AntiTumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner

Gastroenterology

Volumn 140, Issue 1, 2011, Pages 221-230.e3

  Vos, Anne Christine W ^a   Wildenberg, Manon E ^a   Duijvestein, Marjolijn ^a   Verhaar, Auke P ^a   Van Den Brink, Gijs R ^a   Hommes, Daniel W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Autoimmunity; IBD; Inflammatory Response; Type 2 Macrophage

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; FC RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; INFLIXIMAB; LIPOCORTIN 5; ANTIINFLAMMATORY AGENT; CASPASE 3; CELL SURFACE RECEPTOR; CYTOKINE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOSUPPRESSIVE AGENT; LECTIN; MACROGOL DERIVATIVE; MANNOSE BINDING LECTIN; MANNOSE RECEPTOR; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; CELL ISOLATION; COLORIMETRY; CONTROLLED STUDY; CYTOKINE RELEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MACROPHAGE; MIXED LYMPHOCYTE REACTION; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; CELL CULTURE; CELL PROLIFERATION; CROHN DISEASE; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; SECRETION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CASPASE 3; CELL PROLIFERATION; CELLS, CULTURED; CROHN DISEASE; CYTOKINES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LECTINS, C-TYPE; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MACROPHAGES; MANNOSE-BINDING LECTINS; POLYETHYLENE GLYCOLS; RECEPTORS, CELL SURFACE; RECEPTORS, FC; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650459480     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.10.008     Document Type: Article

References (38)

1. D.K. Podolsky Inflammatory bowel disease N Engl J Med 347 2002 417 429
2. C. Fiocchi Inflammatory bowel disease: etiology and pathogenesis Gastroenterology 115 1998 182 205
3. A. Swidsinski, A. Ladhoff, and A. Pernthaler Mucosal flora in inflammatory bowel disease Gastroenterology 122 2002 44 54
4. S. Schreiber, S. Nikolaus, and J. Hampe Tumour necrosis factor [alpha] and interleukin 1[beta] in relapse of Crohn's disease The Lancet 353 1999 459 461
5. S.E. Plevy, C.J. Landers, and J. Prehn A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease J Immunol 159 1997 6276 6282
6. S.J.H. van Deventer Review article: targeting TNF as a key cytokine in the inflammatory processes of Crohns disease the mechanisms of action of infliximab Aliment Pharmacol Ther 13 1999 3 8
7. D. Kontoyiannis, M. Pasparakis, and T.T. Pizarro Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies Immunity 10 1999 387 398
8. S.R. Targan, S.B. Hanauer, and S.J.H. van Deventer A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor {alpha} for Crohn's disease N Engl J Med 337 1997 1029 1036
9. S.B. Hanauer, B.G. Feagan, and G.R. Lichtenstein Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial The Lancet 359 2002 1541 1549
10. S.B. Hanauer, W.J. Sandborn, and P. Rutgeerts Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial Gastroenterology 130 2006 323 333
11. W.J. Sandborn, S.B. Hanauer, and P. Rutgeerts Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial Gut 56 2007 1232 1239 (Pubitemid 47300424)
12. W.J. Sandborn, S.B. Hanauer, and S. Katz Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial Gastroenterology 121 2001 1088 1094
13. P. Rutgeerts, W.J. Sandborn, and R.N. Fedorak Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial Clin Gastroenterol Hepatol 4 2006 888 893
14. B.G. Feagan, W.J. Sandborn, and G. Lichtenstein CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial Aliment Pharmacol Ther 23 2006 617 628
15. T. ten Hove, C. van Montfrans, and M.P. Peppelenbosch Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease Gut 50 2002 206 211
16. J.M.H. Van den Brande, H. Braat, and G.R. van den Brink Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease Gastroenterology 124 2003 1774 1785
17. A. Lgering, M. Schmidt, and N. Lgering Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway Gastroenterology 121 2001 1145 1157
18. H. Mitoma, T. Horiuchi, and H. Tsukamoto Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab Arthritis Rheum 58 2008 1248 1257
19. T. Arora, R. Padaki, and L. Liu Differences in binding and effector functions between classes of TNF antagonists Cytokine 45 2009 124 131
20. E. Louis, G.Z. El, and S. Vermeire Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease Aliment Pharmacol Ther 19 2004 511 519
21. R.A. Clynes, T.L. Towers, and L.G. Presta Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat Med 6 2000 443 446
22. J. Zalevsky, I.W. Leung, and S. Karki The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates Blood 113 2009 3735 3743
23. H. Mitoma, T. Horiuchi, and N. Hatta Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-[alpha] Gastroenterology 128 2005 376 392
24. H.P. de, E.C. de Bruin, and E. Klein-Kranenbarg Caspase-3 activity predicts local recurrence in rectal cancer Clin Cancer Res 13 2007 5810 5815
25. C. Bedini, F. Nasorri, and G. Girolomoni Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function Br J Dermatol 157 2007 249 258
26. Z. Kaymakcalan, P. Sakorafas, and S. Bose Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor Clin Immunol 131 2009 308 316
27. G. Cartron, L. Dacheux, and G. Salles Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene Blood 99 2002 754 758
28. S. Dall'Ozzo, S. Tartas, and G. Paintaud Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship Cancer Res 64 2004 4664 4669
29. F. Bibeau, E. Lopez-Crapez, and F.F. Di Impact of Fc{gamma}RIIa-Fc{gamma} RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan J Clin Oncol 27 2009 1122 1129
30. H.M. Horton, M.J. Bernett, and E. Pong Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia Cancer Res 68 2008 8049 8057
31. E.J. Louis, H.E. Watier, and S. Schreiber Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study Pharmacogenet Genomics 16 2006 911 914
32. J.M. Woof, and D.R. Burton Human antibody-Fc receptor interactions illuminated by crystal structures Nat Rev Immunol 4 2004 89 99
33. V. Kodelja, C. Muller, and S. Tenorio Differences in angiogenic potential of classically vs alternatively activated macrophages Immunobiology 197 1997 478 493
34. M.M. Hunter, A. Wang, and K.S. Parhar In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice Gastroenterology 138 2010 1395 1405
35. Y. Takada, T. Hisamatsu, and N. Kamada Monocyte chemoattractant protein-1 contributes to gut homeostasis and intestinal inflammation by composition of IL-10-producing regulatory macrophage subset J Immunol 184 2010 2671 2676
36. F. Tubach, D. Salmon, and P. Ravaud Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry Arthritis Rheum 60 2009 1884 1894
37. F.A. Verreck, B.T. de, and D.M. Langenberg Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria Proc Natl Acad Sci U S A 101 2004 4560 4565
38. P.B. Kang, A.K. Azad, and J.B. Torrelles The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis J Exp Med 202 2005 987 999